Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. Read more on NVO stock here.

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Novo Nordisk A/S, Apollo Global Management, and Blackstone are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares in companies that are ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

Stan Wong, portfolio manager at Scotia Wealth Management, discusses his past stock picks and how they're doing in the market ...

The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested the latest economic data and Trump's response to Canada and EU tariffs. The S&P 500 closed in correction territory.

A produtora do Ozempic, Novo Nordisk, planeja fabricar mais medicamentos para o mercado dos Estados Unidos localmente; a ...

Here is how the Barron’s Roundtable members’ picks performed. Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the ...